A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms

Trial Profile

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs APR 246 (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jun 2018 Results (As of Feb 12th, 2017,n =9) presented at the 23rd Congress of the European Haematology Association.
    • 17 Jun 2018 Results presented in an Aprea Media Release.
    • 17 Jun 2018 According to an Aprea media release, this trial is financially supported by the MDS Foundation and the Aplastic Anemia and MDS International Foundation as administrator for the Evans MDS Clinical Research Consortium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top